|
|
||||||||
1 Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW; and 2 Wolfson Institute for Biomedical Research, University College London, London WC1E 6BT, United Kingdom
| |
ABSTRACT |
|---|
|
|
|---|
Incubation of rat aortas with endotoxin
and interferon-
for 24 h resulted in an aortic oxygen
consumption that was substantially inhibited and strongly oxygen
dependent (37% inhibition at 160 µM O2 and 62%
inhibition at 80 µM O2 relative to untreated aortas). This respiratory inhibition was reversed by a nitric oxide (NO) scavenger (oxyhemoglobin) or by an inhibitor of inducible NO
synthase [N-(3-(aminomethyl)benzyl)acetamide · 2HCl,
1400W], but not by an inhibitor of soluble guanylate cyclase
(1H-[1,2,4]oxadiazolo[4,3-a]-quinoxalin-1-one). Addition of 1 µM NO to untreated aortas caused rapid and reversible inhibition of oxygen consumption that was greater at lower oxygen concentrations. Incubation of endothelial cells isolated from rat
aortas with endotoxin and interferon-
for 24 h resulted in a
steady-state NO concentration of ~0.5 µM and 90% inhibition of
cellular oxygen consumption that was immediately reversed by an NO
scavenger (oxyhemoglobin). These results suggest that during inflammation and sepsis, tissue respiration may be substantially reduced due to inhibition by NO of cytochrome oxidase.
aorta; endothelial cells; mitochondria; inducible nitric oxide synthase; oxygen
| |
INTRODUCTION |
|---|
|
|
|---|
NITRIC OXIDE (NO) can regulate oxygen supply to tissues by activating soluble guanylate cyclase in vascular smooth muscle, resulting in vascular relaxation and increased blood flow (16, 23). However, NO can also potentially regulate tissue oxygen consumption by binding to the oxygen-binding site of cytochrome oxidase, resulting in reversible inhibition of mitochondrial respiration (5, 7, 9, 31). Binding of NO to cytochrome oxidase is competitive with oxygen, and at physiological levels of oxygen in tissue (roughly 30 µM O2) half-maximal inhibition of respiration occurs at 60 nM NO (7). This concentration is similar to that required for half-maximal activation of soluble guanylate cyclase (45 nM NO) (1). Higher concentrations of NO or its derivatives peroxynitrite and S-nitrosothiols can irreversibly inhibit respiration at multiple sites within mitochondria (4, 10, 14, 15, 20, 26). Reversible inhibition of oxygen consumption by NO has been found in isolated cytochrome oxidase (7, 13, 40), mitochondria (9, 25, 31), and cultured cells (6, 11, 19). In vivo it has been observed that inhibitors of NO synthase cause large increases in tissue and whole body oxygen consumption that are not attributable to any changes in vascular supply (17, 18, 21, 22, 33, 34), suggesting that basal release of NO tonically inhibits tissue respiration in vivo (41, 42). However, it is unclear whether any such NO inhibition of tissue respiration is mediated by a direct action of NO on mitochondrial respiration or indirectly, e.g., via cGMP.
Induction of the inducible isoform of NO synthase (iNOS) by endotoxin and cytokines results in a high, sustained concentration of NO (27), giving rise to reversible inhibition of cellular respiration rate in astrocytes (6) and cells coincubated with iNOS-expressing macrophages (8). iNOS expression also causes irreversible inhibition of mitochondrial respiratory components in astrocytes (3), hepatocytes (36), tumor cells (15, 37), and vascular smooth muscle cells (12, 38).
During local inflammation or the systemic inflammation of sepsis, iNOS
is induced in a wide range of tissue cells (29, 30). Sepsis or endotoxemia can cause hypotension, vascular insufficiency, lactic acidosis, and multiple organ failure, and these symptoms have
been associated with excessive NO production from iNOS (29, 30,
39). Mitochondrial dysfunction has also been implicated in
sepsis, and in principle septic symptoms could be due to NO inhibition
of mitochondrial respiration alone (28, 32). We set out to test 1) whether the induction of iNOS in the
aorta and endothelial cells by endotoxin and interferon-
would
result in a significant inhibition of respiration, and 2)
the mechanism of any such inhibition, its reversibility, and
sensitivity to oxygen concentration.
| |
METHODS |
|---|
|
|
|---|
Wistar rats (12-16 wk old) were euthanized with
CO2. Thoracic aortas were removed, cleaned of adhering fat
and connective tissue in Hanks' balanced salt solution supplemented
with 5 µM indomethacin, and cut into ~4-mm rings. Rings were
incubated for 24 h at 37°C in DMEM (without serum) plus 500 IU/ml penicillin and streptomycin in an incubator gassed with 95%
air-5% CO2. Alternatively, to induce iNOS, aortic rings
were incubated for 24 h in DMEM (plus 500 IU/ml penicillin and 500 IU/ml streptomycin) supplemented with 10 µg/ml lipopolysaccharide
(LPS endotoxin from Salmonella typhimurium; Sigma) and 50 U/ml interferon-
. For measurement of respiratory rate, aortic rings
were washed with Krebs buffer, mounted on steel hooks, and put into 1 ml of Krebs-HEPES buffer (in mM: 118 NaCl, 4.8 KCl, 1.2 KH2PO4, 1.2 MgSO4, 1 CaCl2, 11 glucose, and 25 HEPES, pH 7.4) plus 0.5 mM
L-arginine. Oxygen consumption by aortic rings was measured
in a sealed and stirred vessel with a Clarke-type oxygen electrode
built into the bottom of the vessel (Rank Brothers, Bottisham)
maintained at 37°C.
Endothelial cells were isolated from rat aortas by digestion (7 min at
37°C) with 3 mg/ml collagenase (Sigma C-0130) in medium 199 and
cultured in DMEM plus 15% fetal calf serum, 5 ng/ml basic fibroblast
growth factor, 500 IU/ml penicillin, and 500 IU/ml streptomycin in an
incubator gassed with 95% air-5% CO2 at 37°C. Respiratory measurements were made on 7-9th passage cultures that were ~80% confluent. Cells were activated by adding 10 µg/ml LPS (endotoxin from S. typhimurium, Sigma) and 50 U/ml
interferon-
to the cultures for 24 h before respiratory
measurements. To measure oxygen consumption, cells were removed from
culture flasks by gentle scraping and centrifuged and resuspended at
~3 million cells per millimeter in the Krebs-HEPES buffer (content
given above) plus 0.1 mM L-arginine. Of this cell
suspension, 0.7 ml was added to a sealed, stirred vessel containing
both oxygen and NO (World Precision Instruments) electrodes maintained
at 37°C (7). The NO electrode was calibrated with
NO-saturated, deoxygenated water, assuming this contains 2 mM NO
(6).
| |
RESULTS |
|---|
|
|
|---|
We tested whether the induction of iNOS in rat aortic rings by
endotoxin and interferon-
would inhibit aortic oxygen consumption. Figures 1 and
2 show that the oxygen consumption of
rings maintained in culture conditions with endotoxin and
interferon-
for 24 h was strongly inhibited relative to rings
cultured in the absence of endotoxin and interferon-
. Moreover, the
oxygen consumption of endotoxin- and interferon-
-treated rings
became strongly oxygen dependent, so that the rate of oxygen
consumption was almost proportional to oxygen concentration
over the physiological range up to 160 µM O2 (Figs. 1 and
2). Reoxygenation of hypoxic rings returned the oxygen consumption rate
to the previous high, normoxic rate (data not shown). In contrast, the
oxygen consumption of untreated rings was relatively oxygen
independent, remaining linear until low oxygen levels were reached
(Figs. 1 and 2).
|
|
To test whether the inhibition of respiration was rapidly reversible
and due to NO, we added either a NO scavenger (oxyhemoglobin) or an
iNOS inhibitor
[N-(3-(aminomethyl)benzyl)acetamide · 2HCl, 1400W] to the endotoxin- and interferon-
treated rings before measuring oxygen consumption. These additions resulted in reversal of
the respiratory inhibition (Figs. 1 and 2), indicating that the
inhibition of oxygen consumption was rapidly reversible and due to NO
from iNOS.
Because most of the physiological effects of NO are mediated by
stimulation of soluble guanylate cyclase, we tested whether a specific
inhibitor of this enzyme
(1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, ODQ) could reverse the inhibition of respiration in endotoxin- and interferon-
-treated rings. ODQ did not reverse the respiratory inhibition (Fig. 2), indicating that the NO inhibition of respiration was not mediated by cGMP.
To test whether NO alone could cause respiratory inhibition, we added
authentic NO (1 µM) to control rings. This caused an immediate
inhibition of aortic respiration, which completely reversed, however,
during several minutes (Fig. 1), indicating that NO is a potent,
reversible inhibitor of aortic respiration. Moreover, NO inhibition of
aortic respiration was greater at lower oxygen concentrations (Fig. 1)
and was insensitive to the soluble guanylate cyclase inhibitor ODQ
(data not shown). All of these results in aortic rings are consistent
with endotoxin and interferon-
causing inhibition of aortic
respiration via NO inhibition of cytochrome oxidase in competition with oxygen.
We further tested whether induction of iNOS in aortic endothelial cells
in culture would result in significant inhibition of cellular
respiration and whether any such inhibition would be reversible.
Figures 3 (representative traces) and
4 (mean data) show that endothelial cells
activated for 24 h with endotoxin and interferon-
produced NO
in the presence of L-arginine (steady-state concentration
of 0.54 ± 0.11 µM NO) and that cellular respiration was
substantially inhibited relative to untreated cells (92%
inhibition). This inhibition was immediately reversed on
addition of the NO scavenger oxyhemoglobin. This is again consistent
with NO from iNOS causing potent but reversible inhibition of cellular
respiration via NO binding to cytochrome oxidase.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
We have shown here that incubation with endotoxin and
interferon-
causes a substantial inhibition of oxygen consumption in both isolated aortas and aortic endothelial cells. This inhibition is
largely or completely reversible by an NO scavenger or iNOS inhibitor,
suggesting that NO from iNOS is reversibly inhibiting respiration.
Treatment of mice with endotoxin has previously been shown to reduce myocardial oxygen consumption ex vivo, an effect that was reversed by addition of an inhibitor of NO synthase (24). This inhibition of respiration did not occur in animals that were knockout for iNOS (24).
We have also shown that addition of 1 µM authentic NO causes rapid
and reversible inhibition of aortic respiration, which is greater at
lower oxygen concentrations. The NO-induced inhibition of respiration
is likely to be due to NO binding to cytochrome oxidase, because we
have previously shown that this causes rapid, reversible inhibition
that is competitive with oxygen and occurs over the range of NO
concentrations used here (5, 7). This is also consistent
with the finding that endotoxin- and interferon-
-treated aortic
rings have an oxygen consumption rate that is almost proportional to
oxygen level, whereas untreated rings or treated rings supplemented with an NO scavenger or iNOS inhibitor have oxygen consumption rates
that are relatively insensitive to oxygen level.
It has previously been found that endotoxin and interferon-
treatment of cultured vascular smooth muscle cells for 48 h
resulted in an irreversible inhibition of mitochondrial respiration,
attributed to activation of poly-ADP ribosyltransferase (PARS or PARP)
and subsequent NAD+ and ATP depletion (38).
However, in the conditions of our experiments, we found no significant
irreversible inhibition of cellular respiration at 24 h, although
this does not exclude such an inhibition appearing later or in
different conditions. In particular, in vivo neutrophil recruitment and
activation during inflammation may provide a source of superoxide from
which peroxynitrite may be derived and which might cause an
irreversible inhibition of respiration.
A substantial inhibition of cellular respiration by iNOS-derived NO in competition with oxygen has important implications for inflammation and sepsis. It has been suggested that tissue dysoxia during septic shock, and the consequent organ failure, may be due to inhibition of respiration by NO (24, 28, 32). Furthermore, although no experimental evidence is available at present, it is likely that inhibition of respiration also contributes to the vasodilatation and hyporeactivity to vasoconstrictors.
Inflammation and sepsis are known to be accompanied by glycolysis, increased production of lactate, and inhibition of tissue function (32, 35). Our present and previous findings suggest that these changes might indeed be due to inhibition of respiration by NO and the ensuing oxidative stress (2, 5, 8, 24).
| |
ACKNOWLEDGEMENTS |
|---|
This work was supported by the Biotechnology and Biological Sciences Research Council and British Heart Foundation. S. Moncada was the recipient of an Medical Research Council grant.
| |
FOOTNOTES |
|---|
Present address for A. Matthias: Dept. of Medicine, University of Queensland, Royal Brisbane Hospital, Herston 4029, Australia.
Address for reprint requests and other correspondence: V. Borutaite, Dept. of Biochemistry, Univ. of Cambridge, Tennis Court Rd., Cambridge CB2 1QW, UK (E-mail: vb207{at}mole.bio.cam.ac.uk).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 12 March 2001; accepted in final form 24 July 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Bellamy, TC,
and
Garthwaite J.
Sub-second kinetics of the nitric oxide receptor, soluble guanylate cyclase, in intact cerebellar cells.
J Biol Chem
276:
4287-4292,
2001
2.
Beltran, B,
Mathur A,
Duchen MR,
Erusalimsky JD,
and
Moncada S.
The effect of nitric oxide on cell respiration: a key to understanding its role in cell survival or death.
Proc Natl Acad Sci USA
97:
14602-14607,
2000
3.
Bolanos, JP,
Peuchen S,
Heales SJR,
Land JM,
and
Clark JB.
Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes.
J Neurochem
63:
910-916,
1994[ISI][Medline].
4.
Brown, GC.
NO and mitochondrial respiration.
Biochim Biophys Acta
1411:
351-369,
1999[Medline].
5.
Brown, GC.
Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase.
Biochim Biophys Acta
1504:
46-57,
2001[Medline].
6.
Brown, GC,
Bolanos JP,
Heales SJR,
and
Clark JB.
NO produced by activated astrocytes rapidly and reversibly inhibits cellular respiration.
Neurosci Lett
193:
1-4,
1995[ISI][Medline].
7.
Brown, GC,
and
Cooper CE.
Nanomolar concentrations of NO reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase.
FEBS Lett
356:
295-298,
1994[ISI][Medline].
8.
Brown, GC,
Foxwell N,
and
Moncada S.
Transcellular regulation of cell respiration by NO generated by activated macrophages.
FEBS Lett
439:
321-324,
1998[ISI][Medline].
9.
Cleeter, MWJ,
Cooper JM,
Darley-Usmar VM,
Moncada S,
and
Schapira AHV
Reversible inhibition of cytochrome oxidase, the terminal enzyme of the mitochondrial respiratory chain, by NO.
FEBS Lett
345:
50-54,
1994[ISI][Medline].
10.
Clementi, E,
Brown GC,
Feelisch M,
and
Moncada S.
Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective role of glutathione.
Proc Natl Acad Sci USA
95:
7631-7636,
1998
11.
Clementi, E,
Brown GC,
Foxwell N,
and
Moncada S.
On the mechanisms by which vascular endothelial cells regulate their oxygen consumption.
Proc Natl Acad Sci USA
96:
1559-1562,
1999
12.
Geng, Y,
Hansson GK,
and
Holme E.
Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells.
Circ Res
71:
1268-1276,
1992
13.
Giuffre, A,
Sarti P,
D'Itri E,
Buse G,
Soulimane T,
and
Brunori M.
On the mechanism of inhibition of cytochrome c oxidase by NO.
J Biol Chem
271:
33404-33408,
1996
14.
Heales, JR,
Bolanos JP,
Stewart VC,
Brookes PS,
Land JM,
and
Clark JB.
NO, mitochondria and neurological disease.
Biochim Biophys Acta
1410:
215-228,
1999[Medline].
15.
Hibbs, JJB,
Taintor RR,
Vavrin Z,
and
Rachlin EM.
NO: a cytotoxic activated-macrophage effector molecule.
Biochem Biophys Res Commun
157:
87-94,
1988[ISI][Medline].
16.
Ignarro, LJ.
Introduction and overview.
In: Nitric Oxide: Biology and Pathobiology. San Diego, CA: Academic, 2000, p. 3-19.
17.
Ishibashi, Y,
Duncker DJ,
Zhang J,
and
Bache RJ.
ATP-sensitive K+ channels, adenosine, and NO-mediated mechanisms account for coronary vasodilation during exercise.
Circ Res
82:
346-359,
1998
18.
King, CE,
Melinyshyn MJ,
Mewburn JD,
Curtis SE,
Winn MJ,
Cain SM,
and
Chapler CK.
Canine hindlimb blood flow and oxygen uptake after inhibition of EDRF/NO synthesis.
J Appl Physiol
76:
1166-1171,
1994
19.
Laffranchi, R,
Gogvadze V,
Richter C,
and
Spinas GA.
NO stimulates insulin secretion by inducing calcium release from mitochondria.
Biochem Biophys Res Commun
217:
584-591,
1996.
20.
Lizasoain, I,
Moro MA,
Knowles RG,
Darley-Usmar V,
and
Moncada S.
Nitric oxide and peroxynitrite exert distinct effects on mitochondrial respiration which are differentially blocked by glutathione or glucose.
Biochem J
314:
877-880,
1996.
21.
Loke, KE,
Forfia PR,
Recchia FA,
Xu XB,
Osorio JC,
Ochoa M,
Gawryl M,
and
Hintze TH.
Bovine polymerized hemoglobin increases cardiac oxygen consumption and alters myocardial substrate metabolism in conscious dogs: role of nitric oxide.
J Cardiovasc Pharmacol
35:
84-92,
2000[ISI][Medline].
22.
Loke, KE,
McConnell PI,
Tuzman JM,
Shesely EG,
Smith CJ,
Stackpole CJ,
Thompson CI,
Kaley G,
Wolin MS,
and
Hintze TH.
Endogenous endothelial NO synthase-derived NO is a physiological regulator of myocardial oxygen consumption.
Circ Res
84:
840-845,
1999
23.
Moncada, S,
Palmer RM,
and
Higgs EA.
Nitric oxide: physiology, pathology, and pharmacology.
Pharmacol Rev
43:
109-142,
1991[ISI][Medline].
24.
Orsi, A,
Rees DD,
Beltran B,
and
Moncada S.
Physiological regulation and pathological inhibition of tissue respiration by nitric oxide in vivo.
In: The Biology of Nitric Oxide, , edited by Moncada S,
Gustafsson LE,
Wiklund NP,
and Higgs EA.. London: Portland, 2000, part 7, p. 35.
25.
Poderoso, JJ,
Carreras MC,
Lisdero C,
Riobo N,
Schopfer F,
and
Boveris A.
NO inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles.
Arch Biophys Biochem
328:
85-92,
1996.
26.
Radi, R,
Rodriguez M,
Castro L,
and
Telleri R.
Inhibition of mitochondrial electron transport by peroxynitrite.
Arch Biochem Biophys
308:
89-95,
1994[ISI][Medline].
27.
Rees, DD,
Cellek S,
Palmer RM,
and
Moncada S.
Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock.
Biochem Biophys Res Commun
173:
541-547,
1990[ISI][Medline].
28.
Rees, DD,
Higgs EA,
and
Moncada S.
Nitric oxide and the vessel wall.
In: Hemostasis and Thrombosis, edited by Colman RW,
Hirsh J,
Marder VJ,
Clowes AW,
and George NJ.. Philadelphia, PA: Lippincott, Williams and Wilkins, 2000, p. 673-682.
29.
Rees, DD,
Monkhouse JE,
Cambridge D,
and
Moncada S.
Nitric oxide and the haemodynamic profile of endotoxin shock in the conscious mouse.
Br J Pharmacol
124:
540-546,
1998[ISI][Medline].
30.
Ruetten, H,
and
Thiemermann C.
Nitric oxide and septic shock.
In: Nitric oxide: Biology and Pathobiology. San Diego, CA: Academic, 2000, p. 747-757.
31.
Schweizer, M,
and
Richter C.
NO potently and reversibly deenergizes mitochondria at low oxygen tension.
Biochem Biophys Res Commun
204:
169-175,
1994[ISI][Medline].
32.
Singer, M,
and
Brealey D.
Mitochondrial dysfunction in sepsis.
Biochem Soc Symp
66:
149-166,
1999[Medline].
33.
Shen, W,
Hintze TH,
and
Wolin MS.
NO: an important signalling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption.
Circulation
92:
3505-3512,
1995
34.
Shen, W,
Xu X,
Ochoa M,
Zhoa G,
Wolin MS,
and
Hintze TH.
Role of NO in the regulation of oxygen consumption in conscious dogs.
Circ Res
75:
1086-1095,
1994
35.
Spitzer, JJ.
Bacterial endotoxin effects on carbohydrate utilization and transport.
Biochem Soc Trans
23:
998-1002,
1995[ISI][Medline].
36.
Stadler, J,
Billiar TR,
Curran RD,
Stuehr DJ,
Ochoa JB,
and
Simmons RL.
Effect of exogenous and endogenous nitric oxide on mitochondrial respiration of rat hepatocytes.
Am J Physiol Cell Physiol
260:
C910-C916,
1991
37.
Stuehr, DJ,
and
Nathan CF.
NO: a macrophage product responsible for cytostasis and respiratory inhibition in tumour target cells.
J Exp Med
169:
1543-1555,
1989
38.
Szabo, C,
Zingarelli B,
and
Salzman AL.
Role of poly-ADP ribosyltransferase activation in the vascular contractile and energetic failure elicited by exogenous and endogenous nitric oxide and peroxynitrite.
Circ Res
78:
1051-1063,
1996
39.
Titheradge, MA.
Nitric oxide in septic shock.
Biochim Biophys Acta
1411:
437-455,
1999[Medline].
40.
Torres, J,
Darley-Usmar V,
and
Wilson MT.
Inhibition of cytochrome c oxidase in turnover by NO: mechanisms and implications for control of respiration.
Biochem J
312:
169-173,
1995.
41.
Wolin, MS,
Xie YW,
and
Hintze TH.
Nitric oxide as a regulator of tissue oxygen consumption.
Curr Opin Nephrol Hypertens
8:
97-103,
1999[ISI][Medline].
42.
Zhao, G,
Bernstein RD,
and
Hintze TH.
Nitric oxide and oxygen utilization: exercise, heart failure and diabetes.
Coron Artery Dis
10:
315-320,
1999[ISI][Medline].
This article has been cited by other articles:
![]() |
C. Nunez, V. M. Victor, R. Tur, A. Alvarez-Barrientos, S. Moncada, J. V. Esplugues, and P. D'Ocon Discrepancies Between Nitroglycerin and NO-Releasing Drugs on Mitochondrial Oxygen Consumption, Vasoactivity, and the Release of NO Circ. Res., November 11, 2005; 97(10): 1063 - 1069. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. L Gallagher, J. P Newman, L. R Green, and M. A Hanson The effect of low protein diet in pregnancy on the development of brain metabolism in rat offspring J. Physiol., October 15, 2005; 568(2): 553 - 558. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liu, C. Cheng, N. Zorko, S. Cronin, Y.-R. Chen, and J. L. Zweier Biphasic modulation of vascular nitric oxide catabolism by oxygen Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2421 - H2426. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fiorucci, A. Mencarelli, E. Distrutti, M. Baldoni, P. del Soldato, and A. Morelli Nitric Oxide Regulates Immune Cell Bioenergetic: A Mechanism to Understand Immunomodulatory Functions of Nitric Oxide-Releasing Anti-Inflammatory Drugs J. Immunol., July 15, 2004; 173(2): 874 - 882. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Hintze Prologue: Nitric oxide-hormones, metabolism, and function Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2253 - H2255. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |